Cargando…
A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
BACKGROUND: Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor pr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519532/ https://www.ncbi.nlm.nih.gov/pubmed/32977754 http://dx.doi.org/10.1186/s12885-020-07410-2 |
_version_ | 1783587590774980608 |
---|---|
author | Kawahara, Takashi Kato, Masashi Tabata, Kenichi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tsumura, Hideyasu Iwamura, Masatsugu Uemura, Hiroji Miyoshi, Yasuhide |
author_facet | Kawahara, Takashi Kato, Masashi Tabata, Kenichi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tsumura, Hideyasu Iwamura, Masatsugu Uemura, Hiroji Miyoshi, Yasuhide |
author_sort | Kawahara, Takashi |
collection | PubMed |
description | BACKGROUND: Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor prognostic marker in bladder cancer, upper-urothelial carcinoma, adrenocortical carcinoma, penile cancer, and prostate cancer. This study examined the importance of the NLR as a prognostic marker for castration-resistant prostate cancer (CRPC) patients who received abiraterone acetate or enzalutamide. METHODS: A total of 805 prostate cancer patients developed in CRPC status were enrolled in this study. Of these patients, 449 received abiraterone acetate (ABI; 188 cases) or enzalutamide (ENZ; 261 cases) treatment, and the pre-treatment NLR values of these patients were obtained. We investigated the prognosis in those with higher and lower NLR values. RESULTS: The median NLR was 2.90, and a receiver operating characteristics analysis suggested a candidate cut-off point of 3.02. The median overall survival (OS) was 17.3 months in the higher NLR group (≥3.02) and 27.3 months in the lower NLR group (< 3.02) (p < 0.0001). This trend was also observed in both the ABI and ENZ groups (ABI: 29.3 vs. 15.1 months; ENZ: NR vs. 19.5 months; p < 0.0001 and < 0.0001, respectively). A multivariate analysis revealed that a higher NLR was an independent risk factor. The NLR value was thus shown to be correlated with the prostate cancer progression. CONCLUSIONS: A higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ. The NLR was positively correlated with prostate cancer progression. |
format | Online Article Text |
id | pubmed-7519532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75195322020-09-29 A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment Kawahara, Takashi Kato, Masashi Tabata, Kenichi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tsumura, Hideyasu Iwamura, Masatsugu Uemura, Hiroji Miyoshi, Yasuhide BMC Cancer Research Article BACKGROUND: Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor prognostic marker in bladder cancer, upper-urothelial carcinoma, adrenocortical carcinoma, penile cancer, and prostate cancer. This study examined the importance of the NLR as a prognostic marker for castration-resistant prostate cancer (CRPC) patients who received abiraterone acetate or enzalutamide. METHODS: A total of 805 prostate cancer patients developed in CRPC status were enrolled in this study. Of these patients, 449 received abiraterone acetate (ABI; 188 cases) or enzalutamide (ENZ; 261 cases) treatment, and the pre-treatment NLR values of these patients were obtained. We investigated the prognosis in those with higher and lower NLR values. RESULTS: The median NLR was 2.90, and a receiver operating characteristics analysis suggested a candidate cut-off point of 3.02. The median overall survival (OS) was 17.3 months in the higher NLR group (≥3.02) and 27.3 months in the lower NLR group (< 3.02) (p < 0.0001). This trend was also observed in both the ABI and ENZ groups (ABI: 29.3 vs. 15.1 months; ENZ: NR vs. 19.5 months; p < 0.0001 and < 0.0001, respectively). A multivariate analysis revealed that a higher NLR was an independent risk factor. The NLR value was thus shown to be correlated with the prostate cancer progression. CONCLUSIONS: A higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ. The NLR was positively correlated with prostate cancer progression. BioMed Central 2020-09-25 /pmc/articles/PMC7519532/ /pubmed/32977754 http://dx.doi.org/10.1186/s12885-020-07410-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Kawahara, Takashi Kato, Masashi Tabata, Kenichi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tsumura, Hideyasu Iwamura, Masatsugu Uemura, Hiroji Miyoshi, Yasuhide A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title_full | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title_fullStr | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title_full_unstemmed | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title_short | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
title_sort | high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519532/ https://www.ncbi.nlm.nih.gov/pubmed/32977754 http://dx.doi.org/10.1186/s12885-020-07410-2 |
work_keys_str_mv | AT kawaharatakashi ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT katomasashi ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT tabatakenichi ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT kojimaippei ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT yamadahiroshi ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT kamihiraosamu ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT tsumurahideyasu ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT iwamuramasatsugu ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT uemurahiroji ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT miyoshiyasuhide ahighneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT kawaharatakashi highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT katomasashi highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT tabatakenichi highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT kojimaippei highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT yamadahiroshi highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT kamihiraosamu highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT tsumurahideyasu highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT iwamuramasatsugu highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT uemurahiroji highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment AT miyoshiyasuhide highneutrophiltolymphocyteratioisapoorprognosticfactorforcastrationresistantprostatecancerpatientswhoundergoabirateroneacetateorenzalutamidetreatment |